HRTX(Heron Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $86.35M | $107.67M | $127.04M | $144.28M | $154.90M |
| 毛利润 | $40.33M | $52.80M | $61.94M | $105.64M | $113.56M |
| 营业利润 | −$217.83M | −$174.66M | −$110.61M | −$11.53M | −$2.54M |
| 净利润 | −$220.68M | −$182.02M | −$110.56M | −$13.58M | −$20.20M |
| 经营现金流 | −$203.35M | −$146.91M | −$58.79M | −$22.53M | −$27.59M |
| 自由现金流 | −$206.38M | −$148.74M | −$60.33M | −$24.23M | −$27.91M |
| 摊薄每股收益 | $-2.24 | $-1.67 | $-0.80 | $-0.09 | $-0.12 |